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Abstract
Background: Mesenchymal stromal cells (MSCs) have emerged as a more beneficial alternative to conventional therapy
and may offer a potential cure for unmet medical needs. MSCs are known to possess strong immunomodulatory and
anti-inflammatory properties. Moreover, they promote angiogenesis and tissue regeneration through the secretion of
trophic factors. For these reasons, the past decade witnessed a sharp increase in the number of clinical trials conducted
with stem cells for various vascular diseases requiring angiogenesis. In this study, we evaluated the in vitro
angiogenic potency of Stempeucel®, which is an allogeneic pooled human bone marrow-derived mesenchymal
stromal cell (phBMMSC) product. We previously established the safety of Stempeucel® in our pre-clinical studies,
and clinical trials conducted for critical limb ischaemia and acute myocardial infarction.
Methods: Because the proposed mechanism of action of phBMMSCs is mainly through the secretion of pro-angiogenic
cytokines, we developed a surrogate potency assay by screening various batches of large-scale expanded phBMMSCs for
the expression of angiogenic factors and cytokines through gene expression and growth factor analyses, followed
by in vitro functional assays.
Results: The well characterized angiogenic vascular endothelial growth factor (VEGF) was selected and quantified
in twenty six manufactured batches of phBMMSCs to establish consistency following the United States Food and
Drug Administration recommendations. According to recommendations 21 CFR 211.165(e) and 211.194(a)(2), we
also established and documented the specificity and reproducibility of the test methods employed through
validation. Moreover, we also attempted to elucidate the mechanism of action of the cell population to ensure
appropriate biological activity. The functional role of VEGF has been established through in vitro angiogenic
assays and a dose-dependent correlation was observed with in vitro functional results.
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Conclusions: The data generated from this study suggest the selection of VEGF as a single surrogate marker to
test the angiogenic potency of phBMMSCs. Our study reports the quantification of VEGF in twenty six batches of
large-scale manufactured phBMMSCs, and a concentration-dependent correlation of secreted VEGF to endothelial
cell functions of migration, proliferation and tube formation, in the conditioned medium obtained from nine
phBMMSC batches. To our cognizance, this is the first study in which a single angiogenic factor (VEGF) has been
qualified as a surrogate potency marker through all three in vitro functional assays to determine the angiogenic
potency of the phBMMSC population.
Keywords: Potency assay, Angiogenesis, Pooled human bone marrow-derived mesenchymal stromal cell,
Vascular endothelial growth factor, Endothelial tube formation
Background
Angiogenesis is a physiological process of new blood
vessel formation from pre-existing vasculature, playing
an orchestrated role in the growth and development of
tissues and organs as well as in the process of wound
healing [1]. In tissues requiring revascularization, endo-
thelial cells migrate, proliferate and differentiate to form
primitive tubular networks, which are regulated by pro-
angiogenic growth factors and cytokines [2]. The primi-
tive tubular network requires maturation and stability,
which is controlled by a ‘dynamic angiogenic balance’,
regulated by angiogenic stimulators and inhibitors [3].
The induction of new vasculature is stimulated either by
the administration of pro-angiogenic factors through
recombinant proteins/genes or by progenitor cell popu-
lations, which could secrete multiple pro-angiogenic cy-
tokines [4]. Both of these approaches have been well
tolerated, although larger clinical trial data are required
to demonstrate the safety and efficacy of such therapy
using optimal delivery methods [5]. Varying degrees of
success in cell-based therapeutic angiogenesis have been
achieved by the intramuscular administration of endo-
thelial progenitor cells (EPCs) [6, 7], peripheral blood
mononuclear cells (PBMNCs) [8], bone marrow mono-
nuclear cells (BMMNCs) [9–11] and bone marrow-
derived mesenchymal stromal cells (BMMSCs) [12].
Recently, mesenchymal stromal cells (MSCs) obtained
from various tissues have gained importance in regen-
erative medicine because of their multipotent activity,
including short-term engraftment, paracrine function
and differentiation to endothelial cells [13–15]. Among
various tissues, BMMSCs have been extensively charac-
terized and used in clinical studies due to their vast ex-
vivo expansion potential and their ability to perform
multiple biological functions simultaneously to promote
tissue regeneration in vivo [16]. In this study, we
progressively developed an angiogenic potency assay for
Stempeucel®, which consists of adult human bone
marrow-derived, pooled, culture-expanded MSCs (pooled
human BMMSCs (phBMMSCs)). The development and
characterization of the phBMMSC population has been
published previously [17–20]. Owing to the fact that strik-
ing variations have been observed in the secretome profile
of different donors, we have developed a pooling technol-
ogy to minimize such donor-specific variability and have
generated data demonstrating that a pooled MSC popula-
tion is more consistent and stable in secreting angiogenic
and other cytokines that are critical for regenerative
capacity of these cells in comparison with single donor-
derived MSCs (Thej et al., manuscript in preparation). In
addition, our published clinical trials conducted in
critical limb ischaemia (CLI) patients using phBMMSCs
clearly demonstrated that these pooled cells were safe
[19] and therapeutically effective in patients suffering
from CLI due to Buerger’s disease [20].
As a global industrial standard for cell therapy prod-
ucts (CTPs), the development of in vitro potency assays
based on the mechanism of action for a particular
disease indication in large-scale expanded cells becomes
essential. Potency is one of the critical quality control
measures required for a CTP to demonstrate its bio-
logical activity, which should ideally be related to the
intended therapeutic response. The probable mechanism
of action by which MSCs elicit an angiogenic response is
through their paracrine activity [14, 21]. The secretion
of pro-angiogenic and vascular stability factors, such as
vascular endothelial growth factor (VEGF), angiopoietin-
1 (Ang-1), stromal-derived factor-1 (SDF-1), interleukin
(IL)-8, IL-6, hepatocyte growth factor (HGF) and trans-
forming growth factor beta-1 (TGF-β1), play a role in
the recruitment of endogenous endothelial cells which
subsequently undergo proliferation and differentiation
into new blood vessels both in vitro and in vivo [22, 23].
In order to develop a suitable angiogenic potency assay
for Stempeucel® based on the reported mechanism of
action, we screened the cells for the expression of widely
reported pro-angiogenic genes and further quantified the
corresponding growth factors in various batches of large-
scale expanded allogeneic phBMMSCs. In due course we
selected VEGF – a single, consistently expressed angio-
genic factor and one of the most extensively studied
growth factors responsible for angiogenesis – as the
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surrogate potency marker, and further validated its mech-
anism of action and in vitro functional role.
Methods
Cell culture
Stempeucel® is a bone marrow-derived, ex-vivo ex-
panded, pooled, allogeneic human MSC population that
has been characterized previously [17, 24] (Additional
file 1: Figure S1). Briefly, BMMNCs were separated from
the bone marrow by the Ficoll density gradient method
(1.077 g/ml density). BMMNCs accumulated at the buffy
coat layer were plated into T-75 flasks (BD Biosciences,
San Jose, CA, USA) in the medium comprising DMEM-
KO (Gibco, Carlsbad, CA, USA), 10% fetal bovine serum
(FBS; Hyclone, Waltham, MA, USA), 100 U/ml of Pen-
strep (Gibco) and 100 U/ml of Glutamax (Gibco).
BMMNCs from three different donors were expanded in-
dividually up to passage 1 (P1). The cells from P1 were
pooled in an equal ratio and plated for expansion to sub-
sequent passages at a plating density of 1000 cells/cm2.
The addition of 2 ng/ml of basic fibroblast growth factor
(bFGF; Sigma-Aldrich, St. Louis, MO, USA) was intro-
duced into the medium at P2. The cells were further sub-
cultured up to five passages in 10 cell stacks (Corning,
NY, USA). The pooled allogeneic human BMMSC popula-
tion at P5 was considered Stempeucel®.
Human foreskin fibroblasts (HFFs; Lonza, Switzerland)
were cultured in DMEM-KO, 10% FBS, 100 U/ml of
Penstrep and 100 U/ml of Glutamax. HFFs were used
for assays at P6 and P7.
Umbilical cords for isolating human umbilical vein
endothelial cells (HUVECs) were obtained with the
informed consent of the donors using the guidelines ap-
proved by the Institutional Committee for Stem Cell
Research and Therapy and Institutional Ethics Commit-
tee at Manipal Hospital, Bangalore, India. The umbilical
vein was washed three times with HBSS, and endothelial
cells from the basement membrane were detached using
0.2% collagenase 1 (Sigma-Aldrich). Cells were cultured
in endothelial growth medium 2 (EGM-2; Lonza), using
0.2% gelatin (Sigma-Aldrich) as an attachment substrate.
The cells were characterized for endothelial markers,
CD31, CD34, VE-Cadherin and Von Willebrand factor
(vWF) by flow cytometry (BD LSR II; BD Biosciences)
and gene expression by reverse transcriptase PCR
(Additional file 2: Figure S2). All cells were grown at
37 °C in a 5% CO2 incubator (Binder, Bohemia, NY, USA).
Real-time polymerase chain reaction
Total cellular RNA was isolated using an RNeasy mini
kit (Qiagen, Hilden, Germany). The RNA samples were
treated with RNAase-free DNase I (Ambion, Thermo
Fischer Scientific, Waltham, MA, USA) according to the
manufacturer’s instructions and were reverse-transcribed
into cDNA using a high-capacity cDNA reverse tran-
scription kit (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions. The
transcripts were amplified using SYBR green (Applied
Biosystems). The gene-specific primers and primer
sequences are presented in Table 1. A reverse tran-
scriptase negative control was taken from each sample,
and a no-template blank served as the negative control.
Gene expression was normalized to the housekeeping
gene β-Actin which was used as an internal standard. Sub-
sequently, ΔΔCT was calculated against a fibroblast cell
line, HFF. Similarly, VEGFR1, VEGFR2 and VEGFR3 ex-
pression in HUVECs was normalized against the same
cells grown in endothelial growth medium (EGM) and
expressed as the fold-change.
Preparation and collection of the conditioned medium
from phBMMSCs
phBMMSCs from twenty six different batches were
thawed and plated at a density of 1 × 106 cells per T-75
flask in duplicates. The cultures were fed with 10 ml of
DMEM-KO, 10% FBS, 100 U/ml of Glutamax, 100 U/ml
of Penstrep and 2 ng/ml of bFGF. The conditioned
medium (CM) was collected at the end of 48 and 72 h
from the T-75 flasks and used for growth factor estima-
tions and in vitro functional assays. Complete medium
without cells was also incubated for 72 h and used as a
control for background determination. The collected
media were spun down at 1500 rpm for 5 min to elimin-
ate cell debris, filtered through a 0.22-μm syringe filter
(Merck-Millipore, NJ, USA), aliquoted and stored at –
80 °C until they were used for subsequent assays.
Secretome analysis by growth factor array
The control medium and CM from six phBMMSC batches
were analysed for the presence of cytokines, chemokines
and growth factors by performing a semi-quantitative
human growth factor antibody-based array (RayBio®
Human Growth Factor Array AAH-GF-1-8; Ray Biotech,
Norcross GA, USA). The experiment was performed as per
the manufacturer’s instructions and chemiluminescence
was recorded using ImageQuant LAS 4000 (GE Healthcare,
MA, USA). The data recorded were analysed using ImageJ
software (NIH). The relative intensities of individual growth
factors were calculated as arbitrary units after background
correction and normalized to blot intensities obtained with
the control medium. The complete array layout is depicted
in Additional file 3: Table S1a.
Enzyme-linked immunosorbent assay
Human angiogenic cytokines, VEGF, Ang-1, SDF-1α, IL-
6, IL-8, HGF and TGF-β1 in the CM were estimated
using enzyme-linked immunosorbent assay (ELISA) Kits
(R&D Systems, Minneapolis, MN, USA) according to
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the manufacturer’s directions. Control medium was also
assayed in each ELISA; any non-specific detection of
growth factors/cytokines was subtracted from the respect-
ive CM values. The samples were assayed in duplicates.
Cell migration assay
The cell migration assay was performed using a Transwell
two-chamber cell culture method and Transwell inserts
(Corning, Cambridge,MA, USA) with an 8-μm-pore polycar-
bonate membrane. HUVECs were serum starved for 18 h in
the endothelial basal medium (EBM) supplemented with 0.1%
FBS. The cells were then trypsinized and reconstituted in the
EBM at a density of 1 × 105 cells/100 μl. Next, 1 × 105 cells/
well were plated into the upper chamber of the Transwell in-
sert. In the lower chamber, 0.65 ml of EGM, complete
medium, serum-freemedium (SFM) or CM from phBMMSC
was added. The phBMMSCCMwith 10 μg/ml ofmonoclonal
mouse IgG anti-human VEGF neutralizing antibody (Clone #
26503; R&D Systems) or IgG isotype control (Abcam, Cam-
bridge, MA, USA) was used for additional conditions.
HUVECs were allowed to migrate for 18 h at 37 °C in a hu-
midified incubator. The non-migrated cells were removed
carefully using a pre-wet cotton swab, following which the
membrane was fixed with 4% paraformaldehyde and stained
with haematoxylin for 10 min. After washing, the membrane
was mounted on a slide with Dibutylphthalate Polystyrene
Xylene (DPX; Merck-Millipore, MA, USA), and the cells that
migrated from the upper to the lower side of the membrane
were counted under a bright-field microscope at 100× object-
ive (100×magnification, Nikon 90imicroscope). All of the as-
says were performed in triplicates.
Cell proliferation assay
HUVECs were plated at a density of 2 × 103 cells/well in 96-
well plates and cultured for 24 h in 200 μl/well of the EGM.
The cells were then washed twice with HBSS and serum-
starved for 18 h in the EBM supplemented with 0.1% FBS.
The serum starvation medium was replaced with equal vol-
umes of EGM, control medium, CM, CM containing anti-
VEGF neutralizing antibody (10 μg/ml) or IgG isotype con-
trol (10 μg/ml), SFM or Axitinib (0.25 nM, 0.29 nM and 1.2
nM) (Cayman Chemical, MI, USA). HUVECs were allowed
to proliferate for 72 h. Then 5-bromo-2′-deoxyuridine
(100 μM) was added (1:1000 in SFM) at the 48th hour, and
its uptake by the cells was measured using a colorimetric cell
proliferation ELISA kit (Merck-Millipore, NJ, USA).
To determine the effect of CM on VEGFR1, VEGFR2 and
VEGFR3 gene expression, HUVECs were plated at a density
of 5 × 103 cells/cm2 in six-well dishes (BD Bioscience) in
EGM. The following day, HUVECs were serum starved for
18 h in EBM supplemented with 0.1% FBS. CM from two
batches of phBMMSCs were incubated alone or with anti-
VEGF antibody (10 μg/ml) on HUVECs, and with
EGM,which served as control. HUVECswere allowed to pro-
liferate for 72 h. The cells were then harvested and processed
further for RT-PCR analysis.
In vitro endothelial tube formation assay
Growth factor-reduced (GFR) Matrigel (BD Bioscience) was
thawed on ice at 4 °C overnight. Ten microlitres of Matrigel
was plated onto each inner well of the μ-angiogenesis slides
(IBIDI, Germany) and allowed to solidify at 37 °C for
30 min. 1 × 104 HUVECs were reconstituted in CM only,
CM containing anti-VEGF neutralizing antibody (10 μg/ml),
CM with IgG isotype control (10 μg/ml), complete medium,
EGM or SFM to a total volume of 50 μl and plated on the
GFR Matrigel. The plates were incubated for 6 h in a hu-
midified incubator at 5% CO2 and 37 °C. Images were taken
using an inverted phase-contrast microscope (Nikon) under
4× and 10× objectives. The tube length was measured using
WimTube (Wimasis, GmbH, Germany) from the 4× magni-
fication images of three wells for each condition. The experi-
mental samples and controls were assayed in triplicates.
Table 1 Primer list- Real Time PCR
Markers Forward primer Reverse primer Tm Product length
β-Actin CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 60 250bp
VEGF-A GCAGAATCATCACGAAGTGG GCATGGTGATGTTGGACTCC 60 234bp
TGF-β1 CAGATCCTGTCCAAGCTG TCGGAGCTCTGATGGTGTT 56 270bp
Ang-1 GCTTACCAGATTCACACTGTTCC TTGCTACCTTGCCAACAACAACTG 60 612bp
IL-6 CACAGACAGCCACTCACCTC TTTTCTGCCAGTGCCTCTTT 60 137bp
HGF ATGCATCCAAGGTCAAGGAG TTCCATGTTCTTGTCCCACA 61 349bp
SDF-1α/CXCL12 TGCCAGAGCCAACGTCAAG CAGCCGGGCTACAATCTGAA 60 73bp
VEGFR1 CGTAGAGATGTACAGTGAAA GGTGTGCTTATTTGGACATC 55 306bp
VEGFR2 TTACAGATCTCCATTTATTGC TTCATCTCACTCCCAGACT 60 498bp
VEGFR3 CTGGACCGAGTTTGTGGAGG GTCACATAGAAGTAGATGAGCCG 60 138bp
Tm melting temperature, VEGF-A vascular endothelial growth factor A, TGF-β transforming growth factor beta, Ang-1 angiopoietin-1, IL interleukin, HGF hepatocyte
growth factor, SDF-1 stromal-derived factor-1, VEGFR1 vascular endothelial growth factor receptor 1, VEGFR2 vascular endothelial growth factor receptor 2, VEGFR3
vascular endothelial growth factor receptor 3
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Statistical analysis
The data were analysed using GraphPad Prism 5 soft-
ware (GraphPad Software, Inc., La Jolla, CA, USA;
http://www.graphpad.com). Pairs of data sets were ana-
lysed for statistical significance using one-way ANOVA,
linear regression analysis or Student’s t test (95% confi-
dence interval). p < 0.05 was considered significant. The
results were presented as means ± SEM.
Results
Screening the angiogenic predisposition of phBMMSCs
Human BMMSCs are known to express and secrete a
battery of pro-angiogenic growth factors/cytokines that
are necessary for neo-angiogenesis and repairing vascu-
lar damage in CLI and other ischaemic indications. Be-
cause the pooled population of human BMMSCs has
been shown to increase blood flow in human clinical
trials and in the pre-clinical animal models, we wanted
to determine the angiogenic expression and secretion
profile of our phBMMSCs. The screening of pro-
angiogenic genes such as VEGF, HGF, Ang-1, SDF-1/
CXCL12, IL-6, IL-8 and TGF-β1 by quantitative real
time polymerase chain reaction (qRT-PCR) showed that
all six batches of phBMMSCs expressed higher levels of
mRNAs corresponding to VEGF (1.19 ± 0.17), HGF (409
± 187), Ang-1 (100 ± 34.0), IL-6 (3.0 ± 1.2), IL-8 (39.0 ±
19.0) and TGF-β1 (0.59 ± 0.49) compared with the HFF
cell line, which was used as control. The only exception
was that the HFF cells expressed higher levels of SDF-1
mRNA than phBMMSCs (–0.44 ± 0.02). We also
observed less variation in VEGF expression among the
phBMMSC batches tested (Fig. 1a). The CM from the
phBMMSCs (n = 6) was further evaluated for secretome
profile using the growth factor array kit. We observed
predominant expression of VEGF and insulin growth
factor binding protein 6 (IGFBP-6) with an arbitrary unit
of 20,855 ± 3566 and 22,522 ± 3528, respectively (Fig. 1b).
In addition to the array analysis, we also quantified the
selected angiogenic cytokines secreted by the same six
batches of phBMMSCs in which the angiogenic gene ex-
pression was quantified. The cells secreted high levels of
VEGF (2.6 ± 0.7 ng/ml/million cells; %CV = 25.2), HGF
(31.8 ± 40 pg/ml/million cells; %CV = 78.2), SDF-1α (0.7
± 0.54 ng/ml/million cells; %CV = 73.6), Ang-1 (1.3 ±
1.15 ng/ml/million cells; %CV = 96.6), IL-6 (6.3 ± 3.6 ng/
ml/million cells; %CV = 52.4), IL-8 (18.1 ± 14.2 ng/ml/
million cells; %CV = 72.2) and TGF-β1 (1.2 ± 0.3 ng/ml/
million cells; %CV = 28.6) (Fig. 1c). Upon discerning the
consistency in the mRNA expression and the secretion
level of VEGF, we further evaluated the VEGF secretion
across several passages (P4–P7) (Fig. 1d). The secreted
amounts of VEGF in the CM of phBMMSCs across
these four passages were observed to be similar with no
significant differences (Fig. 1d). Thus, the consistency we
observed with regards to VEGF expression in the cells
and secretion in the corresponding CM, in comparison
with other angiogenic factors tested, led us to select
VEGF as a surrogate potency marker and to further
evaluate its role in different functional angiogenic assays.
Validation of VEGF as a surrogate angiogenic potency
marker for phBMMSCs
To determine the range of VEGF secretion by phBMMSCs
in a large number of batches, we quantified the amount of
VEGF in the CM from twenty six manufactured batches
produced over a period of five years and several of these
batches were used for pre-clinical studies and phase I and
II clinical trials. The mean value of VEGF at 48 h was found
to be 1.7 ± 0.7 ng/ml and that at 72 h was 2.8 ± 1.0 ng/ml
for 1 × 106 cells plated (Fig. 2a). We also determined the ro-
bustness of the assay method by quantifying VEGF in ten
batches of phBMMSCs by two different operators on the
same day and by a single operator performing the assay at
two different time points for the same batches of CM
(Fig. 2b, c). The data showed no significant differences be-
tween the two permutations and confirmed the reproduci-
bility and consistency of the VEGF quantification assay.
VEGF secreted by phBMMSCs induces signal transduction
via the upregulation of VEGF receptors
Based on the accumulated literature evidence on the role of
VEGF in inducing angiogenesis, we wanted to determine
the mechanism by which such functions are brought about
by phBMMSCs. To elucidate the VEGF receptor-mediated
signalling, we blocked the VEGF receptors in the HUVECs
using Axitinib [25], a small molecule that is known to in-
hibit VEGF receptors 2, 3 and 1 at concentrations of 0.25
nM, 0.29 nM and 1.2 nM, respectively. Upon blocking the
VEGF receptors, the cells were allowed to proliferate in the
presence of the CM obtained from phBMMSCs: we ob-
served 102 ± 7.7% proliferation in the 50% CM group, con-
sidering the EGM group as 100% proliferation. HUVEC
proliferation in the 50% CM with Axitinib at concentrations
of 0.25 nM (VEGFR2), 0.29 nM (VEGFR2, VEGFR3) and
1.2 nM (VEGFR2, VEGFR3, VEGFR1) were 6.4 ± 1.8%, 7.6
± 0.7% and 4.9 ± 1.1% respectively; these differences were
not found to be statistically significant although the highest
concentration of Axitinib showed maximum inhibition of
HUVEC proliferation (Fig. 3a). Because we could not deter-
mine which receptor was specifically involved in the process,
we further evaluated the mRNA expression of all three
VEGF receptors on the HUVECs primed with the same
CM. We observed a considerable upregulation of all three
VEGF receptors. However, neutralization of secreted VEGF
using anti-human VEGF mAb did not abolish the expression
of VEGFR1 and VEGFR3, whereas a significant downregula-
tion of VEGFR2/KDR was evident (p= 0.01) (Fig. 3b–d)
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Furthermore, an upregulation of the downstream genes,
PI3K and AKT-1, was observed (Fig. 3e), thus con-
firming that the mechanism of VEGFR2-mediated
signalling is operative for the phBMMSC population
in the regulation of angiogenesis. A schematic diagram to
illustrate this phenomenon is shown (Fig. 3f).
Confirmation of the functional role of VEGF through
in vitro angiogenic assays
To further confirm that the VEGF secreted by phBMMSCs
functionally induces angiogenesis, we performed parallel ex-
periments using rhVEGF and the CM from the phBMMSC
population. For this purpose, several HUVEC primary lines
were generated and characterized for the expression of endo-
thelial cell specific markers CD31, CD34 and vWF by flow cy-
tometry and RT-PCR (Additional file 2: Figure S2). HUVECs
harvested at P3–P5 were used for all in vitro assays. We per-
formed HUVEC Transwell migration assays using rhVEGF
solution in SFM at dilutions ranging from 8 ng/ml to 31.2 pg/
ml (Fig. 4a). Except for the 8 ng/ml concentration, all other
rhVEGF dilutions matched the concentration of secreted
VEGF in the phBMMSC CM serially diluted from 100%
(4 ng/ml VEGF) to 0.19% (7.8 pg/ml) (Fig. 4b). The 50% di-
luted phBMMSC CM, which contained 2 ng/ml of secreted
VEGF brought about 51% greater migration than the 2 ng/ml
rhVEGF (Fig. 4a, b). As expected, a dose-dependent reduction
in themigrated cells was observed in both the rhVEGFand se-
creted VEGF groups, while the threshold concentration of
VEGF necessary for HUVECmigration was determined to be
125 pg/ml. The neutralization of rhVEGF and the secreted
VEGF using an anti-VEGF-blocking antibody at a concentra-
tion of 10 μg/ml inhibited HUVEC migration by 84% in the
2 ng/ml group of rhVEGF and by 85% inhibition in the 2 ng/
ml secreted VEGF compared with the respective IgG isotype
values. No significant difference in the migration of HUVECs
was observed between the CM-treated and the isotype-
treated cells (Fig. 4b).
Next, we compared the ability of rhVEGF and VEGF
secreted by phBMMSCs with matched concentrations to
determine the effect of VEGF in HUVEC proliferation.
Fig. 1 a qRT-PCR analysis of seven angiogenic genes: VEGF, HGF, SDF-1, Ang-1, IL-6, IL-8 and TGF-β1 in six batches of phBMMSCs. Relative fold expressionwas
depicted after normalization to the housekeeping gene β-Actin as an internal standard and subsequent normalization using human foreskin fibroblast (HFF) cells
for the same genes.b Secretome analysis of controlmedium and phBMMSCCMusing 41 growth factor antibody arrays detected by chemiluminescence; a few
detected growth factorsmarked in boxes. cQuantification of seven selected angiogenic growth factors/cytokines using human-specific ELISAs in same six
batches of phBMMSCs. d Quantification of VEGF by ELISA in CM from five batches of phBMMSCs from P4 to P7; one-way ANOVA revealed no significant
difference in VEGF levels between P4 and P7, p= 0.699. Data presented as mean ± SEM. SEMs shown as error bars. phBMMSC pooled human bone
marrow derived mesenchymal stromal cell, Ang-1 angiopoietin-1, SDF-1 stromal-derived factor-1, bFGF basic fibroblast growth factor, HGF
hepatocyte growth factor, IL interleukin, TGFβ1 transforming growth factor beta-1, VEGF vascular endothelial growth factor
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The rhVEGF alone in the SFM promoted the prolifera-
tion of HUVECs (Fig. 4c); however, considerably higher
proliferation was observed when the HUVECs were in-
cubated in the presence of CM (Fig. 4d). The CM from
the phBMMSCs demonstrated a dose-dependent reduc-
tion in proliferation ranging from a 50% CM containing
2 ng/ml secreted VEGF to a 0.78% CM with 31.2 pg/ml
of secreted VEGF. Neutralization of the secreted VEGF
using the anti-VEGF mAb at a concentration of 10 μg/
ml inhibited HUVEC proliferation up to 31% as com-
pared with CM incubated with IgG isotype, thus indicat-
ing that HUVEC proliferation was partially mediated by
VEGF (Fig. 4d). Similar to the results obtained with
migration, we did not observe any difference in prolifer-
ation of HUVECs when incubated with CM and CM
with IgG isotype.
We further investigated the role of VEGF in the final
stage of in vitro angiogenesis by performing the tube for-
mation assay in GFR Matrigel. We observed that rhVEGF
alone at concentrations ranging from 8 ng/ml to 15.6 pg/
ml did not promote the tube formation of HUVECs in
GFR Matrigel (data not shown). Conversely, the CM from
phBMMSCs significantly promoted tube formation in a
dose-dependent manner, ranging from 50% (2 ng/ml of
VEGF) to the lowest concentration of 0.78% (31.2 pg/ml
VEGF) where initiation of tube formation was detected
(Fig. 4e–q). It should be mentioned that 2 ng/ml of VEGF
containing CM showed maximum tube formation (Fig. 4r).
Addition of the anti-VEGF mAb (10 μg/ml) (Fig. 4p)
inhibited tube formation by >50% compared with the CM
group incubated with IgG isotype. Similar to the results
obtained with migration and proliferation of HUVECs,
tube formation was also unaffected with the addition of
the IgG isotype. Taken together, these functional studies
demonstrate clearly that the VEGF present in the CM was
able to elicit migration, proliferation and tube formation
of HUVECs in vitro (Fig. 4).
Validation of VEGF-mediated in vitro angiogenic function
by phBMMSC batches
To confirm that VEGF is indeed the angiogenic surro-
gate marker for the phBMMSC population, we evaluated
the potential of the secreted VEGF in the CM derived
from nine phBMMSC batches (Fig. 5). The biological
Fig. 2 Quantification and validation of VEGF secreted by phBMMSCs. a VEGF levels in the CM from twenty six batches of phBMMSCs by ELISA.
VEGF level at 48 h was 1.7 ± 0.7 ng/ml/million cells and at 72 h was 2.8 ± 1.0 ng/ml/million cells. b Quantification of VEGF levels in the CM from ten
batches of phBMMSCs estimated by two different operators; no significant differences were observed in the VEGF levels estimated by two different
operators determined by Student’s t test, p = 0.774. c Quantification of VEGF levels in the CM from ten batches of phBMMSCs estimated by a single
operator on two different days; no significant differences were observed in the VEGF levels estimated by a single operator at different time points as
determined by Student’s t test, p = 0.631. Data presented as mean ± SEM. SEMs shown as error bars. VEGF vascular endothelial growth factor
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assays performed were endothelial cell migration, prolif-
eration and tube formation, which represent the entire
process of angiogenesis and correlated with the functional
activity through the secreted VEGF from each batch of
phBMMSCs. First, HUVEC migration was assessed using
the CM from all nine batches of phBMMSCs and the re-
sults are shown in Fig. 5a, b. We observed that the cell mi-
gration was comparable amongst all batches with a 19%
coefficient of variation (Fig. 5b). Upon neutralization of
VEGF, the migration of HUVECs was inhibited by >75%
compared with the corresponding IgG isotype (Fig. 5a).
The correlation of VEGF concentration in each of the
nine batches with the number of migrated cells dis-
played high linearity with a correlation coefficient of
0.78 (p = 0.0014) (Fig. 5b).
Similarly, we also assessed the proliferation of HUVECs
using all nine batches of CMs. The proliferation of
HUVECs was comparable for all batches with a coefficient
of variation of 21% (Fig. 5c). Neutralization of VEGF in the
CM from all of the batches significantly blocked prolifera-
tion of HUVECs by >50% compared with the correspond-
ing IgG isotype. The correlation of VEGF concentration
Fig. 3 Activity of VEGF secreted from phBMMSCs is mediated by VEGFR2. a Proliferation of HUVECs using 50% CM from phBMMSCs and 50% CM
with Axitinib at concentrations of 0.25 nM, 0.29 nM and 1.2 nM to block VEGFR2, VEGFR2 and VEGFR3, and VEGFR2, VEGFR3 and VEGFR1 respectively.
Significant reduction in HUVEC proliferation was observed in the CM with all Axitinib treatment groups, ***p= 0.0001. EGM was used as a positive control
for HUVEC proliferation. Analysis of VEGFR1 (b), VEGFR2 (c) and VEGFR3 (d) fold expression in HUVECs treated with phBMMSC CM and phBMMSC CM with
anti-VEGF mAb by qRT-PCR. Significant reduction only in VEGFR2 expression was observed in the phBMMSC CM with anti-VEGF mAb group compared
with the CM alone group, *p = 0.01. e Analysis of VEGF pathway-dependent markers PI3K and AKT1 in HUVECs cultured in the presence of phBMMSC CM
by qRT-PCR; mRNA expression levels were normalized with housekeeping gene β-Actin as an internal standard and subsequently normalized to expression
levels in HUVECs cultured in EGM as control. Data generated using two batches of phBMMSC CM, assayed in triplicates and presented as mean ± SEM.
f Schematic diagram to depict the possible signal transduction pathway of VEGF secreted by phBMMSCs in HUVECs. SEMs shown as error bars. HUVEC
Human umbilical vein endothelial cell, EGM endothelial growth medium, CM conditioned medium, VEGFR vascular endothelial growth factor receptor,
mAb monoclonal antibody, Ang-1 angiopoietin-1, SDF-1 stromal-derived factor-1, HGF hepatocyte growth factor, IL interleukin, TGF-β transforming
growth factor beta
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quantified from these batches highly correlated with
HUVEC proliferation and was calculated to generate a cor-
relation coefficient value of 0.75 (p = 0.002) (Fig. 5d).
Finally, the in vitro angiogenic tube formation by
HUVECs was assessed for these nine CM batches and
the results are shown in Fig. 5. The extent of tube for-
mation in all of the tested conditions are shown in
Fig. 5e–i. It is clear from the representative images that
the maximum tube length was observed in phBMMSC
CM (Fig. 5g), phBMMSC CM with IgG isotype (Fig. 5h)
Fig. 4 Functional in vitro HUVEC migration, proliferation and tube formation with rhVEGF and phBMMSC CM, followed by inhibition of VEGF activity.
a Transwell migration of HUVECs in response to rhVEGF serially diluted from 8 ng/ml to 31.2 pg/ml in SFM. Significant inhibition of HUVEC migration
was observed in 2 ng/ml rhVEGF with anti-VEGF mAb (10 μg/ml) compared to migration observed with 2 ng/ml rhVEGF concentration, **p = 0.001.
b Transwell migration of HUVECs in response to phBMMSC CM serially diluted with SFM from 100% (4 ng/ml of secreted VEGF) to 0.19% (7.8 pg/ml of
secreted VEGF). The maximum migration of HUVECs was observed at 50% dilution comprising 2 ng/ml secreted VEGF which was significantly inhibited
by anti-VEGF mAb (10 μg/ml) in comparison with phBMMSC CM+ IgG isotype, *p = 0.02, and phBMMSC CM, **p = 0.0009. Threshold for HUVEC proliferation
was observed at 3.125% CM dilution with 125 pg/ml VEGF. c Proliferation of HUVECs in response to rhVEGF serially diluted starting from 8 ng/ml in SFM.
rhVEGF did not effectively induce proliferation and therefore no measurable effect was observed with the anti-VEGF mAb. d HUVEC proliferation with
phBMMSC CM serially diluted from 100% to 0.19% in SFM. Addition of anti-VEGF mAb to the 50% CM significantly reduced proliferation, **p =
0.001, in comparison with CM containing IgG isotype, *p = 0.04. Proliferation in HUVECs initiated at 0.78% CM dilution with 31.2 pg/ml VEGF.
e–q HUVEC tube formation in response to phBMMSC CM serially diluted from 100% to 0.19%. Maximum tube formation was observed at 50%
dilution containing 2 ng/ml secreted VEGF. Significant reduction in tube formation was observed when anti-VEGF mAb was used in 50%
diluted CM, while IgG isotype did not alter the tube formation of HUVECs. r Graphical representation of tube formation induced by phBMMSC
CM at various concentrations. Tube formation seemed to initiate at 0.78% CM dilution. Statistical significance was determined using Student’s
t test. Data presented as mean ± SEM. SEMs shown as error bars. CM conditioned medium, phBMMSC pooled human bone marrow derived
mesenchymal stromal cell, SFM serum-free medium, VEGF vascular endothelial growth factor, HPF high-power field
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Fig. 5 (See legend on next page.)
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and EGM (Fig. 5e) conditions, while complete medium
and CM with anti-VEGF mAb showed similar extent of
vessel formation (Fig. 5f and i respectively). Further-
more, a reduction of tube formation by >50% was ob-
served in the presence of anti-VEGF mAb, while no
such inhibition was observed with the IgG isotype
(Fig. 5j). The average of total tube lengths obtained from
all nine batches of phBMMSC CM and other conditions
are graphically represented in Fig. 5j. Similar to migra-
tion and proliferation, a strong correlation (r2 = 0.8992,
p = 0.0001) was observed between the VEGF concentra-
tion and the tube lengths (Fig. 5k) with a low CV of
18%. Collectively, the data generated by three different
in vitro functional measurements of angiogenesis corre-
lated linearly with the concentration of VEGF present in
the CM generated from the phBMMSC population.
Discussion
Ischaemia is described as the shortage of oxygen in tis-
sues or organs because of the restriction of blood supply
instigated by vasoconstriction, thrombosis, embolism or
vessel rupture in indications such as peripheral arterial
disease and its more severe form, CLI [26]. In CLI
patients there is extensive tissue damage due to severe
blockage or degeneration of blood vessels and these pa-
tients often require therapeutic intervention using pro-
angiogenic therapy. Moreover, CLI is associated with
non-healing ulcers, gangrene and limb amputations
which lead to increased morbidity and mortality rates
[27]. Because conventional therapy is of limited value to
these patients, attempts are being made to determine
whether cell and gene therapy can provide sustainable
benefit to CLI patients.
Cell-based therapeutic angiogenesis is gaining momen-
tum as an alternative to the current revascularization
strategies. Several pre-clinical and clinical studies using
EPCs, autologous CD34+ BMMNCs and autologous or
allogeneic MSCs derived from various tissue sources in-
cluding bone marrow have demonstrated their interaction
with endogenous endothelial cells via paracrine cross-talks
or direct cell-to-cell interaction, thus promoting angiogen-
esis, resulting in limb salvage [6–8, 28]. The first clinical
trial for therapeutic angiogenesis using cell transplantation
(TACT) in PAD patients with autologous BMMNCs and
peripheral blood mononuclear cells, conducted success-
fully by Tateishi-Yuyama et al. in 2002 [8], showed evi-
dence of improvement in multiple clinical parameters in
the patients injected with BMMNCs. Since then, a num-
ber of clinical trials using a variety of cell types have been
completed with different degrees of success [29–32]. A
trial using autologous BMMNCs showed greater clinical
improvements in patients with Buerger’s disease in com-
parison with those with atherosclerotic PAD, and this was
associated with greater EPC migration in response to
VEGF in Buerger’s disease patients [33]. In our own phase
I/II clinical trial where we have established the safety of
phBMMSC administration in CLI patients, we also ob-
served that there is a significant improvement in the ankle
brachial pressure index (ABPI) in the cell-treated group of
patients compared with placebo [19]. Recently, we have
published our phase II clinical data demonstrating that
intra-muscular administration of phBMMSCs in Buerger’s
disease CLI patients resulted in a significant decrease in
rest pain and improvements in ulcer healing and blood
circulation [20]. Moreover, new collateral vessel formation
was also observed in some of these patients suggesting
that the cells were able to initiate neo-angiogenesis. As we
progress towards a phase III clinical trial with CLI pa-
tients, in addition to developing identity, purity and safety
assays, it is critical to develop an angiogenesis-specific po-
tency assay, intended to be applied for disease indications
that require therapeutic angiogenesis, to demonstrate that
the expression of the ‘so-called’ potency marker by the cell
product corroborates with the therapeutic outcome.
Potency assay development requires establishing a clear
connection between the therapeutic cells and their func-
tional activity specific to the intended clinical indication
[34]. It is necessary to develop such an assay or assay
(See figure on previous page.)
Fig. 5 In vitro pro-angiogenic function of secreted VEGF from nine batches of phBMMSCs. a Evaluation of HUVEC migration under various culture
conditions. CM (n= 9) induced significant migration of HUVECs. Migration was unaffected by an isotype-matched antibody (p= 0.1964), while addition of
anti-VEGF mAb caused significant (*p= 0.0001) inhibition of cell migration. Migration of HUVECs in the CM group was significantly higher than that of
control medium, ***p= 0.0004. b Correlation of VEGF concentration in phBMMSC CM (n= 9) with HUVEC migration was observed, r2 = 0.78, **p= 0.0014.
c HUVEC proliferation in response to various culture conditions; phBMMSC CM (n= 9) induced HUVEC proliferation similar to that of EGM and complete
medium, although significant reduction of cell proliferation was observed in the CM group with anti-VEGF mAb in comparison to CM with isotype IgG,
**p= 0.0075. Addition of IgG isotype in the CM did not alter HUVEC proliferation compared with CM alone, p= 0.2985. d Correlation of VEGF
concentration-dependent proliferation of HUVECs was observed with phBMMSC CM (n = 9) with a high correlation coefficient, r2 = 0.75, **p = 0.002.
Representative images of tube formations in e EGM, f control medium, g phBMMSC CM, h IgG isotype, i phBMMSC CM with anti-VEGF mAb, 4×
objective were used for magnification. j phBMMSC CM (n = 9) induces significant tube formation in HUVECs compared with EGM and control medium
(**p= 0.0063). Tube formation was greatly reduced with the addition of anti-VEGF mAb in the CM in comparison with the isotype-matched control group
(**p= 0.0084). Tube formation in HUVECs was unaffected with the addition of IgG isotype (p = 0.2985). k Concentration of VEGF in nine batches of CM
highly correlated to the tube lengths, r2 = 0.89, ***p= 0.0001. Data presented as mean ± SEM. SEMs shown as error bars. CM conditioned medium,
phBMMSC pooled human bone marrow derived mesenchymal stromal cell, EGM endothelial growth medium, VEGF vascular endothelial growth factor, HPF
high-power field
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matrix for allogeneic MSCs in a progressive manner from
the pre-clinical stage through various clinical trial phases
and implemented at the time of phase III trial.
The United States Food and Drug Administration (US
FDA) and European Medicines Agency (EMA) accept
non-functional assays for potency testing, but it is essen-
tial to develop an in vitro or in vivo biologically functional
assay and attempt to correlate the potency of the product,
at least to the in vitro functional assay. Correlating the po-
tency results with the pre-clinical or clinical outcomes is
usually challenging because of their complex, multimodal
mechanism of action, particularly where live cells are used
for treatment.
In this study, based on the existing literature supporting
the therapeutic benefit of BMMSCs in revascularization,
the expression of pro-angiogenic genes was initially
screened in our pooled cell population and the results
clearly demonstrated their pro-angiogenic predisposition
(Fig. 1). The clear demonstration of the presence of pro-
angiogenic growth factors and cytokines at the gene and
protein levels suggested that phBMMSCs can be a thera-
peutically beneficial product for treating diseases in which
tissue angiogenesis is severely impaired. Among the vari-
ous factors we have screened and estimated, VEGF ap-
pears to be expressed consistently and secreted by these
cells in the CM. In addition to VEGF, phBMMSCs secrete
varying amounts of other well characterized angiogenic
growth factors like Ang-1, SDF-1, HGF, IL-6, IL-8 and
TGF-β1. Many of these factors have been shown to have a
specific role in the entire cascade of ‘physiological angio-
genesis’, without which adequate vascularization may not
be possible [35]. The comparable levels of VEGF secretion
by the phBMMSCs across various passages suggested that
the regulation of VEGF synthesis is well controlled in the
manufactured phBMMSC product (Fig. 2). These observa-
tions led us to choose VEGF as a surrogate potency
marker for phBMMSCs that has long been identified as
the primary regulator of angiogenesis [36, 37]. It is note-
worthy that the significance of VEGF in inducing pro-
angiogenesis has not only been restricted to MSCs,
because human neural stem cells (hNSCs) have also been
reported to support angiogenesis in vitro and in vivo and
the proposed mechanism of action is probably governed
by VEGF [38]. Quantitation of VEGF on twenty six manu-
factured batches over a period of five years suggested sta-
bility as well as reproducibility of VEGF secretion by the
manufactured and cryopreserved phBMMSCs; similar
data pertaining to VEGF were shown earlier with Multi-
stem®, a large-scale expanded multipotent adult progenitor
cell (MAPC) product [39]. Based on the VEGF quantita-
tion data obtained from many production batches (Fig. 2),
the level of VEGF may be estimated to be ≥2 ng/ml/mil-
lion phBMMSCs to qualify these cells for eliciting neo-
angiogenic activity.
VEGF is known to bind to its receptors, VEGFR1/Flt-1,
VEGFR2/KDR and VEGFR3, with differential affinity and
associated functions on EPCs [40, 41]. In order to eluci-
date the specificity of the receptor binding of the VEGF
secreted by phBMMSCs, we used Axitinib, a specific
receptor tyrosine kinase blocker, at different concentra-
tions to block the three VEGF receptors [25]. Our results
clearly suggest that VEGF synthesized by phBMMSCs spe-
cifically binds to VEGFR2, because >90% of VEGF binding
was abolished in the presence of Axitinib at the lowest
concentration of 0.25 nM, which is precisely preordained
to neutralize VEGFR2 activation. Additionally, the expres-
sion of all three VEGF receptors was upregulated in the
endothelial cells upon exposure to the CM from
phBMMSCs, while neutralization of the secreted VEGF in
the CM significantly downregulated only VEGFR2 expres-
sion and not the other two receptors, thus indicating the
specificity of VEGF secreted by the phBMMSCs to
VEGFR2. Although VEGFR2 has a lower binding affinity
in comparison with VEGFR1, VEGFR2 has nevertheless
been reported to be the main transducer for VEGF-A
driving endothelial cell survival, migration, proliferation
and their differentiation during vascular tube formation
[41–43]. The survival of endothelial cells in ischaemic
tissues is a key requirement in therapeutic angiogenesis,
and thus we looked into the survival-related down-
stream molecules PI3K and AKT. In our results, we ob-
served an increased expression of PI3K and AKT in the
CM-primed endothelial cells, which further indicates
the specificity of VEGF in promoting endothelial cell
survival.
The contribution of VEGF was also evaluated using
rhVEGF alongside the CM generated by culturing
phBMMSCs at various concentrations to understand
the implication of VEGF in the angiogenic process.
VEGF contributed majorly by facilitating in vitro migra-
tion, proliferation and tube formation of HUVECs
(Figs 4 and 5). Biological assays along with the non-
biological potency assay (e.g. ELISA) could add value to
the potency evaluation of the therapeutic product, and
these assays could be part of the potency assay matrix.
It is also important to note that Stempeucel® has been
shown to ameliorate foot necrosis and limb salvage in an
in vivo murine model of hind-limb ischemia [20, 44]. Our
next logical approach is to determine whether blocking
VEGF immediately after Stempeucel® administration
would obviate neo-angiogenesis in a felicitous pre-clinical
model.
The data presented here suggest a high correlation of
VEGF concentration with in vitro endothelial function,
indicating that prior estimation of VEGF by ELISA can
be considered a categorical, reliable and robust surrogate
marker for angiogenic potency, quantifiable outside a
living system, and also satisfies all regulatory requisites
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for a large-scale, expanded, allogeneic BMMSC popula-
tion, Stempeucel®.
Conclusion
In this article, we have followed a systematic approach
towards developing and qualifying a potency assay as per
the regulatory requirements by screening, estimating and
selecting a single surrogate marker for angiogenesis.
Consistency of the assay was also substantiated by estab-
lishing the reproducibility and mechanism of action as
well as correlating with in vitro functional assays. Taken
together, we propose that VEGF can be considered a sin-
gle surrogate marker for angiogenic potency and set an
example for developing and validating a potency assay for
clinical-grade allogeneic phBMMSCs intended for thera-
peutic angiogenesis in CLI and other vascular diseases.
Additional files
Additional file 1: Figure S1. showing a characterization of phBMMSCs
for MSC-positive surface markers (CD44, CD73, CD90, CD105 and CD166)
and negative markers (CD14, CD19, CD34, CD45, CD133 and HLA-DR),
and indication of viability (inset), by flow cytometry; b differentiation of
phBMMSCs into adipocytes, osteocytes and chondrocytes, stained with
Oil Red O, Alizarin Red and Saffranin O, respectively. (TIF 6151 kb)
Additional file 2: Figure S2. showing a morphology of HUVECs at P1;
b–d characterization of HUVECs using three-colour flow cytometry analysis
for surface markers CD31, CD34 and CD73 indicating high HUVEC purity;
e characterization of HUVECs by reverse transcriptase PCR for endothelial
specific markers, vWF (von Willebrand factor), VE-Cadherin, CD34 and CD31.
(TIF 3909 kb)
Additional file 3: Table S1a. presenting the layout of a chemiluminescence
detection-based growth factor array for Fig. 1b; information provided
by the manufacturer. (TIF 1976 kb)
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